Adicet announces trials in progress poster presentation for adi-001 at 2021 ash annual meeting

Menlo park, calif. and boston, nov. 04, 2021 (globe newswire) -- adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing first-in-class allogeneic gamma delta t cell therapies for cancer and other diseases, today announced that a trials in progress abstract related to the company's lead candidate, adi-001, has been accepted for an oral presentation at the 63rd american society of hematology (ash) annual meeting and exposition being held december 11-14, 2021.
ACET Ratings Summary
ACET Quant Ranking